BETA: Please send your feedback!

Supernus Pharmaceuticals

NAS:SUPN

Pharmaceuticals: Other

$1.95bn
SMALL cap
$36.96 (-0.86%)
13.7626%
since start of 2019
17.94
  • 1
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data Privacy
  • Consumer Health
  • Employee Satisfaction
  • Workplace Safety
  • Corp Gov
  • Ethical Practices
  • Conflict Materials
  • Forced Labor
  • Gender Diversity
  • 1
  • CF
  • PP
  • WC
  • DP
  • CH
  • ES
  • WS
  • CG
  • EP
  • CM
  • FL
  • GD
  • 1
  • 2
  • 3
  • 4
  • 5

About

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi, which treats patients with epilepsy. It also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
website

Headquarters

1550 East Gude Drive
Rockville, MD 20850

Executives

Name Title Gender
Charles W. Newhall, III, MBA Chairman Male
Gregory S. Patrick, MBA CFO, Vice President & Head-Investor Relations Male
Jack A. Khattar, MBA President, CEO, Secretary & Director Male
Padmanabh P. Bhatt, PhD Chief Scientific Officer & Senior Vice President Male
Tami Tillotson Martin Vice President-Regulatory Affairs Female
Stefan K. F. Schwabe, MD, PhD Chief Medical Officer, EVP-Research & Development Male

Mindful Investing Summary

  • 1
  • 2
  • 3
  • 4
  • 5
  • Carbon Footprint N/A
  • Pollution Prevention N/A
  • Water Conservation N/A
  • Data & Privacy Protection N/A
  • Consumer Health, Wellness & Safety N/A
  • Employee Ownership, Satisfaction, Benefits & Pay N/A
  • Workplace Health and Safety N/A
  • Integrity of Corporate Governance N/A
  • Ethical Practices N/A
  • Usage of Conflict Materials N/A
  • Forced Labor N/A
  • Diversity of Corporate Leadership 1

Supernus Pharmaceuticals - Competitors and Related Companies

How Supernus Pharmaceuticals stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.

Supernus Pharmaceuticals

NAS:SUPN

Pharmaceuticals: Other

$1.95bn
SMALL cap
$36.96 (-0.86%)
13.7626%
since start of 2019
17.94
  • 1
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data Privacy
  • Consumer Health
  • Employee Satisfaction
  • Workplace Safety
  • Corp Gov
  • Ethical Practices
  • Conflict Materials
  • Forced Labor
  • Gender Diversity
  • 1
  • CF
  • PP
  • WC
  • DP
  • CH
  • ES
  • WS
  • CG
  • EP
  • CM
  • FL
  • GD
  • 1
  • 2
  • 3
  • 4
  • 5
Loading…